What question did this study set out to answer?

The research aims to investigate the relationship between proton pump inhibitor use and the occurrence of immune-related adverse events in lung cancer patients.

February 5, 2026Open Access

Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study

Key Points

The research aims to investigate the relationship between proton pump inhibitor use and the occurrence of immune-related adverse events in lung cancer patients.
Conducted a retrospective study analyzing patient records.
Examined the incidence of immune-related adverse events (irAEs) associated with proton pump inhibitors.
Evaluated the influence of gut microbiome changes on irAE occurrence.
PPI use was linked to a lower incidence of non-CIP immune-related adverse events.
No significant effect of PPI was noted for CIP-related adverse events.
PPI use was not identified as an independent prognostic factor for irAE occurrence.

Abstract

PPI use was potentially associated with a lower incidence of non-CIP irAEs, whereas no significant effect was observed for CIP. In contrast, PPI use was not an independent prognostic factor, suggesting that irAE occurrence is influenced by multiple factors beyond PPI use. This study highlights the importance of investigating the interplay between PPI exposure, irAE occurrence, and gut microbiome alterations.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Miyamoto et al. (Mon,) studied this question.

synapsesocial.com/papers/69843360f1d9ada3c1fb0853 https://doi.org/https://doi.org/10.1186/s12885-026-15646-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper